INTRODUCTION {#s1}
============

Each year, ovarian cancer is diagnosed in nearly a quarter of a million women around the world, and is responsible for approximately 140, 000 deaths. Due to the asymptomatic nature of early disease, most women present with stage III and IV ovarian cancer, for which the standard of care remains surgery and platinum-based chemotherapy using cisplatin or carboplatin, and taxane agents \[[@R1], [@R2]\]. However, since most ovarian cancers relapse and become drug-resistant, the survival rates remain low \[[@R3]--[@R5]\]. The advanced stages of ovarian cancer are characterized by the increased expression of the pro-inflammatory and pro-angiogenic chemokine IL-8 (CXCL8), which induces tumor cell survival, proliferation, angiogenesis, and metastasis, and correlates with poor prognosis \[[@R6]--[@R12]\].

Even though proteasome inhibition by bortezomib (BZ; Velcade, PS-341) has shown remarkable anti-tumor activity in multiple myeloma, cutaneous T cell lymphoma, and other hematological malignancies, it has been less effective in solid tumors, including ovarian cancer \[[@R13]--[@R18]\]. However, the mechanisms are not fully understood. Nevertheless, BZ has been considered in combination with other therapies, especially the currently used cisplatin, since BZ prevents the cisplatin-induced degradation of cisplatin influx transporter, resulting in enhanced cisplatin uptake and tumor cell killing \[[@R19], [@R20]\]. Thus, understanding the mechanisms responsible for the resistance of ovarian carcinoma to BZ may lead to the development of more effective combination therapies.

The initial rationale behind BZ development and use was its inhibition of the inducible IκBα degradation by 26S proteasome, resulting in the inhibition of nuclear translocation of NFκB subunits and decreased expression of NFκB-dependent anti-apoptotic genes in multiple myeloma cells \[[@R21], [@R22]\]. However, studies from our laboratory have shown that proteasome inhibition also induces nuclear translocation of IκBα, which has a promoter specific effect on the suppression of NFκB-dependent genes \[[@R23], [@R24]\]. While most genes are inhibited by the nuclear IκBα, the IL-8 expression is IκBα independent \[[@R25]\]. Our recent *in vitro* studies have shown that the proteasome inhibition by BZ actually increases the IL-8 expression in cancer cells \[[@R26]--[@R28]\]. In ovarian cancer cells *in vitro*, the BZ increased IL-8 expression is mediated by IKKβ-dependent recruitment of S536-phosphorylated p65 to IL-8 promoter \[[@R27]\], suggesting that inhibition of IKK activity might increase BZ effectiveness in ovarian cancer.

In this study, we tested the hypothesis that IKK inhibition increases BZ effectiveness in reducing tumor growth *in vivo*, in ovarian cancer xenografts. We demonstrate that combination of BZ and the IKK inhibitor Bay 117085 significantly reduces ovarian tumor growth in nude mice when compared to either drug alone. Our results indicate that the underlying mechanisms involve decreased tumor levels of S536P-p65 and its decreased recruitment to IL-8 promoter in tumor tissue, resulting in reduced tumor mRNA levels and plasma concentrations of IL-8. These data suggest that combining BZ with IKK inhibitor is effective and may demonstrate a clinical benefit in the ovarian cancer treatment.

RESULTS {#s2}
=======

Suppression of BZ-induced IL-8 expression enhances BZ pro-apoptotic effect in ovarian cancer cells {#s2_1}
--------------------------------------------------------------------------------------------------

Since we have recently shown that BZ increases the *in vitro* IL-8 expression in ovarian cancer cells \[[@R27]\], we wanted to determine whether the BZ-induced IL-8 expression is responsible for the decreased effectiveness of BZ in ovarian cancer cells. To address this hypothesis, we suppressed the IL-8 expression in BZ-treated ovarian cancer SKOV3 and OVCAR3 cells by siRNA, and evaluated apoptosis by cell death ELISA assay that quantifies the release of nucleosomes into the cytoplasm \[[@R28]\]. As expected, BZ considerably increased both IL-8 mRNA levels (Figure [1A](#F1){ref-type="fig"}) and IL-8 cytokine release (Figure [1B](#F1){ref-type="fig"}) in SKOV3 and OVCAR3 cells transfected with control siRNA. In cells transfected with IL-8 specific siRNA, the IL-8 expression and release were significantly decreased (Figures [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}).

![Suppression of BZ-induced IL-8 expression enhances BZ pro-apoptotic effect in ovarian cancer cells\
SKOV3 and OVCAR3 cells were transfected with control siRNA (blue columns) or IL-8 specific siRNA (red columns), treated 24 hours with 0, 0.1, and 1 μM BZ, and analyzed for IL-8 mRNA expression by real time RT-PCR **A.** and for IL-8 release by ELISA **B.** Apoptosis was analyzed by the cytoplasmic nucleosome enrichment assay in SKOV3 and OVCA3 cells transfected with control or IL-8 specific siRNA and incubated with 0, 0.1, and 1 μM BZ for 24 hours **C.** The values in Figures [1A--1C](#F1){ref-type="fig"} represent the mean +/--SE of four experiments. Asterisks denote a statistically significant (*p* \< 0.05) change compared to cells transfected with the corresponding control siRNA.](oncotarget-06-26347-g001){#F1}

BZ also increased apoptosis in SKOV3 and OVCAR3 cells transfected with control siRNA (Figure [1C](#F1){ref-type="fig"}); this is in an agreement with previous studies demonstrating that proteasome inhibition induces apoptosis in ovarian cancer cells \[[@R29], [@R30]\]. Importantly, the BZ-induced apoptosis was significantly increased in IL-8 siRNA transfected cells compared to cells transfected with control siRNA (Figure [1C](#F1){ref-type="fig"}), indicating that suppression of the BZ-induced IL-8 expression enhances the pro-apoptotic effect of BZ in ovarian cancer cells *in vitro*.

IKK inhibitor Bay 117085 suppresses BZ induced IL-8 expression in ovarian cancer cells {#s2_2}
--------------------------------------------------------------------------------------

Since our data demonstrated that suppression of IL-8 enhances the BZ pro-apoptotic effect (Figure [1](#F1){ref-type="fig"}), and since studies by Mabuchi *et al*. \[[@R31], [@R32]\] indicated that IKK inhibition by the soluble IKK inhibitor Bay 117085 induces apoptosis in ovarian cancer cells, we hypothesized that IKK inhibition by Bay 117085 inhibits the BZ-induced IL-8 expression in ovarian cancer cells. To test this hypothesis, SKOV3 and OVCAR3 cells were pre-incubated 12 hours with 0, 5, and 20 μM Bay 117085 \[[@R31]\], before 24-hour incubation with 0.1 μM BZ, which approximately corresponds to the clinically used BZ concentrations \[[@R33]\], and IL-8 mRNA levels and cytokine release were analyzed by RT-PCR and ELISA, respectively. As shown in Figure [2](#F2){ref-type="fig"}, Bay 117085 significantly decreased the BZ-induced IL-8 mRNA levels (Figure [2A](#F2){ref-type="fig"}) and cytokine release (Figure [2B](#F2){ref-type="fig"}) in ovarian cancer SKOV3 and OVCAR3 cells, suggesting that IKK inhibition by Bay 117085 may enhance the BZ effectiveness in ovarian cancer treatment.

![IKK inhibitor Bay 117085 suppresses BZ-induced IL-8 expression in ovarian cancer cells\
SKOV3 and OVCAR3 cells were pre-incubated 12 hours with 5 or 20 μM Bay 117085, treated 24 hours with 0.1 μM BZ, and analyzed for IL-8 mRNA expression by real time RT-PCR **A.** and for IL-8 release by ELISA **B.** The values in Figure [2](#F2){ref-type="fig"} represent the mean +/--SE of four experiments. Asterisks denote a statistically significant change (\**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001).](oncotarget-06-26347-g002){#F2}

Combination of BZ and Bay 117085 enhances BZ effectiveness in reducing tumor growth in nude mice implanted with ovarian cancer xenografts {#s2_3}
-----------------------------------------------------------------------------------------------------------------------------------------

To investigate whether Bay 117085 enhances BZ effectiveness in ovarian cancer *in vivo*, we examined the effect of BZ and Bay 117085 alone and in combination on the ovarian tumor growth in nude mice. Female athymic nude mice were implanted (s.c.) with SKOV3 cells. After tumors (\~70 mm^3^) developed, the mice were randomly divided into four groups (*n* = 8) injected (i.p.) for 28 days with the following: (a) vehicle control (PBS), (b) Bay 117085 (5 mg/kg) every other day (24), (c) BZ (1 mg/kg) every third day (14), and (d) combination of Bay 117085 (5 mg/kg) and BZ (1 mg/kg). As evaluated by body weight, the treatment regimen was well tolerated since the mice did not lose any weight (Figure [3A](#F3){ref-type="fig"}).

![Combination of BZ and Bay 117085 enhances BZ effectiveness in reducing tumor growth in nude mice implanted with ovarian cancer xenografts\
**A.** Average body weight of mice in four treatment groups (*n* = 8): control, Bay 117085, BZ, and Bay 117085/BZ combination, over the course of four weeks. **B.** Relative tumor volume calculated as the volume at the indicated day divided by the volume at the starting day of treatment. **C.** Images of excised SKOV3 tumors implanted subcutaneously in mice (*n* = 8) after 4 weeks of treatment. **D.** Average weight of the excised tumors (*n* = 8) at the end of the 4-week treatment period. The values in Figure [3](#F3){ref-type="fig"} represent the mean +/--SE. Asterisks denote a statistically significant change (\*\**p* \< 0.01; \*\*\**p* \< 0.001).](oncotarget-06-26347-g003){#F3}

After 28 days of therapy, Bay 117085 reduced the average relative tumor volume by 40% compared to the control group, whereas BZ reduced the average relative tumor volume by 56% (Figure [3B](#F3){ref-type="fig"}). Remarkably, the combination of Bay 117085 and BZ significantly decreased the relative tumor volume compared with control animals (79% tumor reduction, *p* \< 0.001) or individual treatment with Bay 117085 (61% tumor reduction, *p* \< 0.001) or BZ alone (51% tumor reduction, *p* \< 0.001) by the final day of treatment. The reduced tumor volume in mice treated with the combination Bay 117085/BZ therapy corresponded to the appearance of the tumors at the end of the treatment (Figure [3C](#F3){ref-type="fig"}). In addition, the reduced tumor volume in the combination group corresponded to the final average tumor weight at the end of the experiment (Figure [3D](#F3){ref-type="fig"}). The average final tumor weight in the combination group was reduced by 76% (*p* \< 0.001) compared to control mice, 59% compared to Bay 117085-treated mice (*p* \< 0.001), and 56% compared to BZ-treated mice (*p* \< 0.001) (Figure [3D](#F3){ref-type="fig"}). These data indicate that combining the IKK inhibitor Bay 117085 and the proteasome inhibitor BZ has significant anti-tumor effectiveness *in vivo*.

Combination of BZ and Bay 117085 decreases IL-8 expression in nude mice {#s2_4}
-----------------------------------------------------------------------

Since IKK inhibition by Bay 117085 reduced the BZ-induced IL-8 expression in ovarian cancer cells *in vitro* (Figure [2](#F2){ref-type="fig"}), and since BZ/Bay 117085 combination therapy resulted in the slowest tumor growth *in vivo* (Figure [3](#F3){ref-type="fig"}), we reasoned that the combination BZ/Bay 117085 therapy might be associated with the reduced IL-8 expression in implanted ovarian cancer xenografts. To analyze the IL-8 expression *in vivo*, we measured IL-8 mRNA levels in tumor samples, and IL-8 cytokine release in plasma samples obtained from mice at the end of the treatment, by using quantitative RT-PCR and ELISA, respectively. Since mice do not have a homolog of the CXCL8/IL-8 gene, which is present in other species including humans \[[@R34]\], the IL-8 detected in mice tumors and plasma samples was derived from the implanted SKOV3 cell xenografts.

Interestingly, while Bay 117085 or BZ alone did not have a significant effect on the IL-8 mRNA levels in tumors, combination of Bay 117085 and BZ significantly decreased the IL-8 mRNA levels in ovarian tumor xenografts (Figure [4A](#F4){ref-type="fig"}). The IL-8 mRNA levels analyzed in the tumor tissues in the combination group were only 44% compared to the control untreated group (Figure [4A](#F4){ref-type="fig"}). Correspondingly, the Bay 117085/BZ combination therapy significantly reduced the IL-8 plasma levels, while either drug alone did not inhibit the IL-8 release (Figure [4B](#F4){ref-type="fig"}). Compared to mice in the control group, the IL-8 plasma levels in the BZ/Bay 117085 combination group were 50% lower (Figure [4B](#F4){ref-type="fig"}).

![Combination of BZ and Bay 117085 decreases IL-8 expression in nude mice\
**A.** IL-8 mRNA levels analyzed by real time RT-PCR in excised tumors from the four treatment groups (*n* = 8). **B.** IL-8 cytokine release measured by ELISA in mice plasma samples of the four treatment groups (*n* = 8) at the end of the experiment. The values in Figure [4](#F4){ref-type="fig"} represent the mean +/--SE. Asterisks denote a statistically significant change (\**p* \< 0.05) compared to mice in the control untreated group.](oncotarget-06-26347-g004){#F4}

Combination of BZ and Bay 117085 decreases recruitment of S536-p65 to IL-8 promoter in ovarian cancer xenografts {#s2_5}
----------------------------------------------------------------------------------------------------------------

*In vitro*, the IL-8 transcription is regulated by IκBα-independent, promoter specific recruitment of p65 NFκB phosphorylated by IKK at S536 \[[@R27], [@R35], [@R36]\]. Thus, we wanted to determine whether the reduced IL-8 expression and tumor growth in the combination group are associated with decreased levels of S536-phosphorylated p65 and its recruitment to the endogenous IL-8 promoter in ovarian cancer xenografts. To evaluate the S536P-p65 levels in tumors tissues, we analyzed p65, S536P-p65, p50, IκBα, and actin protein levels in whole cell extracts prepared from tumor tissues by immunoblotting.

As shown in Figures [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}, proteasome inhibition by BZ increased the protein levels of p65 in tumor tissues. This is consistent with previous studies demonstrating that p65 undergoes proteasomal degradation \[[@R37]--[@R39]\]. In contrast to p65, p50 levels were not substantially changed between the four groups, indicating that p50 is not subjected to proteasomal degradation *in vivo*. Both Bay 117085 and BZ increased the tumor levels of IκBα, which was highest in the combination group; this is consistent with the well-documented IKK-dependent proteasomal degradation of IκBα \[[@R40], [@R41]\]. The levels of S536-p65 were highest in the control group, and as expected, S536 p65 phosphorylation was significantly reduced in mice treated with the IKK inhibitor Bay 117085 (Figures [5A, 5B](#F5){ref-type="fig"}).

![Combination of BZ and Bay 117085 decreases recruitment of S536-p65 to IL-8 promoter in ovarian cancer xenografts\
**A.** Immunoblotting analysis of p65, p50, IκBα, S536-p65, and control actin in whole cell extracts prepared from excised tumors at the end of the experiment. Representative samples from each treatment group (*n* = 8) are shown. **B.** Densitometric evaluation of p65, p50, and S536P-p65 in whole cell extracts analyzed by immunoblotting in panel A. The values for Bay 117085, BZ, and Bay 117085/BZ were compared to the values for control untreated group, which were considered 100%. The values represent the mean +/−SE (*n* = 8); asterisks denote a statistically significant (*p* \< 0.05) change compared to control untreated group. **C.** Recruitment of p65, p50, and S536P-p65 to endogenous IL-8 promoter in implanted tumors in the four treatment groups of mice (*n* = 8) was analyzed by ChIP and quantified by real time PCR. The data are presented as the difference in occupancy of each protein between the IL-8 promoter and the IGX1A (SA Biosciences) negative control locus, and represent the mean +/--SE (*n* = 8). The asterisk denotes a statistically significant (*p* \< 0.05) change compared to the control untreated group.](oncotarget-06-26347-g005){#F5}

To determine whether the decreased expression of IL-8 in the combination group is associated with the decreased promoter occupancy of S536P-p65 in tumor tissues, we analyzed S536P-p65 recruitment to the endogenous IL-8 promoter by chromatin immunoprecipitation (ChIP). To this end, tumor tissues were homogenized, proteins and DNA were cross-linked with formaldehyde, and chromatin was sheared by sonication. The recruitment of p65, S536P-p65, and p50 to IL-8 promoter in tumor xenografts was measured by ChIP and quantified by real time PCR. As shown in Figure [5C](#F5){ref-type="fig"}, p65 and p50 were not substantially recruited to the IL-8 promoter, and their promoter occupancy was not significantly affected by Bay 117085 or BZ. In contrast, S536P-p65 was considerably recruited to the IL-8 promoter in tumor tissues, and its recruitment was significantly decreased in the combination group.

DISCUSSION {#s3}
==========

The key finding of this study is that combination of BZ and the IKK inhibitor Bay 117085 significantly reduces tumor growth of ovarian cancer xenografts in nude mice when compared to either drug alone. After four weeks of therapy, the combination of Bay 117085 and BZ inhibited the average tumor volume by 61% compared with Bay 117085 alone, and by 51% compared with BZ alone. The average tumor weight in the combination group was decreased by 59% compared to Bay 117085 alone, and by 56% compared to BZ alone. The reduced tumor growth in mice treated with the BZ/Bay 117085 combination was associated with decreased tumor IL-8 mRNA levels and decreased IL-8 concentration in plasma samples. Furthermore, the reduced tumor growth in the combination group was associated with decreased tumor levels of S536P-p65 NFκB, and with the decreased recruitment of S536P-p65 to IL-8 promoter in tumor tissues. These data provide the first *in vivo* evidence that combining BZ with IKK inhibitor is effective and may demonstrate a clinical benefit in the ovarian cancer treatment.

Despite the limited effectiveness of BZ as a single agent in the treatment of ovarian carcinoma and other solid tumors, BZ has been considered in combination with cisplatin and other platinum drugs \[[@R16]--[@R18]\], since it prevents the proteasomal degradation of cisplatin influx transporter, resulting in increased cisplatin uptake and tumor cell killing \[[@R19], [@R20]\]. The original rationale behind BZ development and use in multiple myeloma was the inhibition of NFκB-dependent transcription of anti-apoptotic genes, by blocking the inducible proteasomal degradation of IκBα and nuclear translocation of NFκB subunits \[[@R21], [@R22]\]. However, later studies demonstrated that in unstimulated cells, proteasome inhibition actually induces NFκB activity by increasing stability and activity of IKK \[[@R27], [@R42]\]. Even though in ovarian cancer cells, proteasome inhibition reduces expression of NFκB-dependent anti-apoptotic genes and induces apoptosis \[[@R29], [@R30]\], it also induces IKK-dependent IL-8 expression \[[@R27]\]. Since suppression of the BZ-induced IL-8 expression increases the BZ pro-apoptotic effect in ovarian cancer cells, and since IL-8 levels correlate with ovarian cancer progression \[[@R9]--[@R12]\], these data suggest that the BZ-induced IL-8 expression might represent one of the mechanisms responsible for the decreased effectiveness of BZ in ovarian cancer treatment.

We have recently shown that the mechanisms that regulate the IL-8 expression in ovarian cancer cells *in vitro*, involve IKKβ-dependent S536 phosphorylation of p65, which is specifically recruited to the IL-8 promoter, resulting in increased IL-8 transcription \[[@R27]\]. Interestingly however, while BZ substantially increases the IL-8 expression in ovarian cancer cells *in vitro* \[[@R27]\], BZ alone has only an insignificant effect on the IL-8 mRNA tumor levels and IL-8 plasma concentrations in nude mice. Furthermore, in contrast to inhibiting the BZ-induced IL-8 expression *in vitro*, Bay 117085 alone somewhat increases the IL-8 mRNA tumor levels and IL-8 plasma concentrations *in vivo*. Even though the precise mechanisms are unclear at present, they likely involve additional side effects of BZ and Bay 117085 on other signaling molecules and pathways. In this context, previous *in vitro* studies have shown that in addition to inhibiting the IKK activity, Bay 117085 also has an NFκB-independent effect, and activates mitogen-activated protein kinases (MAPK), extracellular signal-regulated kinases ERK1/2 and p38 kinase in human chondrocytes and monocytic cells, respectively \[[@R43], [@R44]\]. Since *in vitro* studies have shown that the IL-8 expression in ovarian cancer cells is regulated by p38 and ERK1/2 kinases \[[@R45]--[@R47]\], it seems plausible that Bay 117085, as a single agent, increases the IL-8 expression in mice by activating p38 and/or ERK1/2. Intriguingly, however, combination of BZ with Bay 117085 has a synergistic effect on the IL-8 expression in mice, and results in a significantly reduced ovarian tumor growth compared to either drug alone. Even though the regulation of IL-8 expression *in vivo* is complex, and more studies are warranted, one possible mechanism may consist of BZ inhibition of the Bay 117085-induced p38 and/or ERK1/2 pathways, since recent studies have indicated that proteasome inhibition by BZ suppresses MAPK signaling \[[@R48], [@R49]\]. In this model, an individual treatment with BZ or with Bay 117085 has only a modest effect on reducing ovarian tumor growth in mice since it does not significantly inhibit the IL-8 expression. However, combination of BZ and Bay 117085 maximizes the potential of both drugs to inhibit the IL-8 expression and reduce ovarian tumor growth in *vivo*. In ovarian cancer cells *in vitro*, the IL-8 expression is regulated by IKKβ-mediated recruitment of S536P-p65 NFκB to the IL-8 promoter \[[@R27]\]. Since the decreased expression of IL-8 in mice treated with the BZ/Bay 117085 combination is associated with the reduced S536 phosphorylation of p65 and its decreased recruitment to the IL-8 promoter in tumor tissues, these results suggest that the IL-8 expression *in vivo* is also regulated by S536P-p65.

High expression of IL-8 and IKKβ in ovarian cancer tissues has been related to the aggressive nature of this disease, and to the poor outcome \[[@R9]--[@R12], [@R50]--[@R52]\]. Interestingly, epidemiological studies have indicated that the regular use of non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin and diclofenac, is associated with a reduced risk of ovarian cancer \[[@R53]--[@R56]\]. In addition, recent studies have shown that NSAIDs reduce ovarian tumor growth in mice \[[@R57], [@R58]\]. Even though one of the main mechanisms of action of NSAIDs is the inhibition of cyclooxygenase activity, they also inhibit the IKK activity, particularly the activity of IKKβ \[[@R59], [@R60]\]. Although as single agents, IKK inhibitors have failed to exhibit a strong anticancer effect in ovarian cancer, they have been considered in combination with chemotherapy, particularly with cisplatin and paclitaxel, since they inhibit the cisplatin- and paclitaxel-induced NFκB activity in ovarian cancer cells \[[@R31], [@R61], [@R62]\].

Collectively, our data demonstrate that combining the proteasome inhibitor BZ with the IKK inhibitor Bay 117085 significantly reduces ovarian tumor growth in nude mice when compared to either drug alone. Even though additional mechanisms are likely to be involved, our results indicate that the reduced tumor growth is associated with the IKK-dependent decreased S536 phosphorylation of p65 and its decreased recruitment to IL-8 promoter, resulting in reduced IL-8 transcription. To our knowledge, this is the first report demonstrating that IKK inhibition increases BZ effectiveness in reducing ovarian tumor growth *in vivo*, and suggesting that future studies and clinical trials should examine the effect of IKK inhibitors on increasing the BZ effectiveness in ovarian cancer treatment.

MATERIALS AND METHODS {#s4}
=====================

Antibodies and reagents {#s4_1}
-----------------------

Purified polyclonal antibodies against human p65 NFκB (sc-372), phosphorylated p65 NFκB at S536 (sc-33020), p50 NFκB (sc-7178), and IκBα (sc-371) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Purified polyclonal antibody against actin was from Sigma (St. Louis, MO, USA). Horseradish peroxidase (HRP)-conjugated anti-rabbit, anti-mouse and anti-goat secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Bortezomib was obtained from Selleck Chemicals (Houston, TX, USA). The IKK inhibitor Bay 117085 was purchased from Cayman Chemicals (Ann Arbor, MI, USA). All other reagents were molecular biology grade and were from Sigma (St. Louis, MO, USA).

Cell culture {#s4_2}
------------

Human ovarian cancer OVCAR3 and SKOV3 cells were obtained from American Type Culture Collection (ATCC; Rockville, MD, USA). The cells were cultured in RPMI 1640 medium (Invitrogen, Grand Island, NY, USA) supplemented with 10% heat inactivated fetal bovine serum (FBS; Invitrogen, Grand Island, NY) and antibiotics as described \[[@R27]\]. Prior to treatment, cells were seeded (5 × 10^5^ cells/ml) for 24 hours in 6-well plates and grown at 37°C with 5% CO~2~. For *in vitro* experiments, bortezomib and Bay 117085 were dissolved in DMSO, and an equivalent DMSO volume was used as a solvent control.

Transfection with siRNA {#s4_3}
-----------------------

Human IL-8 (sc-39631) and non-silencing (sc-37007) small interfering RNAs (siRNAs) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Prior to transfection, cells were seeded into a 6-well plate and incubated in a humidified 5% CO~2~ atmosphere at 37°C in antibiotic-free RPMI medium supplement with 20% FBS for 24 h to 80% confluence. For each transfection, 80 pmol of either non-silencing siRNA-A control or IL-8 siRNA (Santa Cruz Biotechnology, CA) were used. Cells were transfected for 6 hours in siRNA transfection medium (sc-36868) with siRNA transfection reagent (sc-29528) according to manufacturer\'s instructions (Santa Cruz Biotechnology, Santa Cruz, CA). After transfection, fresh medium with antibiotics was added, and the cells were grown for 24 hours before BZ treatment.

Ovarian cancer xenografts {#s4_4}
-------------------------

All animal procedures were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the NIH, and were approved by the Institutional Animal Care and Use Committee of St. John\'s University. Five-week-old female athymic nude mice (Taconic Farms, NY, USA) were used for tumor xenograft experiments. Mice were maintained on an alternating 12 hours light/dark cycle with *ad libitum* water and rodent chow as described \[[@R63], [@R64]\]. Mice were subcutaneously (s.c.) injected in the right flanks with 5 × 10^6^ of SKOV3 cells in 200 μl of serum free RPMI media. Once the average tumor size reached about 70 mm^3^, mice were randomly divided into four groups (*n* = 8). The control group received the control vehicle (PBS) injected intra-peritoneally (i.p) every other day for four consecutive weeks. The "IKK inhibitor" group received Bay 117085 (5 mg/kg) prepared in PBS, injected i.p. every other day. The "BZ" group received BZ (1 mg/kg) prepared in PBS, injected i.p. every third day. The "combination" group received Bay 117085 every other day, and BZ every third day. Mice were weighed, and tumor volume was monitored by caliper measurement every other day. Tumor volumes were calculated using the following formula: Volume = length × width^2^ × 0.5.

At the endpoint, mice were anesthetized using isoflurane inhalant gas and approximately 1 ml of blood was collected from each mouse by cardiac puncture. The blood samples were centrifuged at room temperature in heparinized tubes to prepare plasma samples, which were stored at −80°C for future IL-8 analysis. Immediately after the blood collection, mice were euthanized using carbon dioxide and tumors were excised, measured, weighed, and collected. Each tumor was cut into two parts; one part was flash frozen in liquid nitrogen and stored in −80°C for future protein extraction and chromatin immunoprecipitation (ChIP). The other half was stored in RNA*later* solution for total RNA extraction.

ELISA {#s4_5}
-----

IL-8 release was measured in cell culture supernatants and mice plasma samples by commercially available IL-8 ELISA kit (R&D, Minneapolis, MN, USA) as described \[[@R27]\].

Apoptosis assay {#s4_6}
---------------

Apoptosis was evaluated using a cell death detection ELISA kit that quantifies the release of nucleosomes into the cytoplasm (Cell Death Detection ELISAPLUS, Roche, Indianapolis, IN, USA) as described \[[@R28]\].

Real time RT-PCR {#s4_7}
----------------

Total RNA was isolated by using RNeasy mini-kit (Qiagen, Valencia, CA, USA). The iScript one-step RT-PCR kit with SYBR Green (Bio-Rad, Hercules, CA, USA) was used as a supermix and 20 ng/μl of RNA was used as template on a Bio-Rad MyIQ Single Color Real-Time PCR Detection System (Bio-Rad). The primers used for quantification of IL-8 and actin mRNA were purchased from SA Biosciences (Frederick, MD, USA).

Western analysis {#s4_8}
----------------

Tumor tissues were rinsed with PBS containing 1 mM PMSF and 1% (v/v) anti-protease cocktail (P8340, Sigma), and homogenized in a lysis buffer containing 0.5M Tris-HCl (pH 6.8), 50% glycerol, 10% SDS and 1% (w/v) bromophenol blue, using dounce homogenizer. The homogenized tissues were immediately boiled (7 min) and centrifuged (5 min, 5, 000 *g*). The supernatants were collected and stored at −80°C. The denatured proteins were separated on 12% SDS gels, and analyzed by immunoblotting as described \[[@R26]--[@R28]\].

Chromatin immunoprecipitation (ChIP) {#s4_9}
------------------------------------

Tumor tissues were homogenized in PBS buffer containing 1% (v/v) anti-protease cocktail (P8340, Sigma) and 1 mM PMSF by using dounce homogenizer. Proteins and DNA were cross-linked by formaldehyde, and cells were washed and sonicated as described \[[@R26]--[@R28]\]. The lysates were centrifuged (15, 000 *g*, 10 min, 4°C), and the supernatant extracts were diluted with ChIP dilution buffer and pre-cleared with Protein A/G Agarose (Santa Cruz, CA, USA) for 2 hours at 4°C. Immunoprecipitation was performed overnight at 4°C, with p65, S536P-p65, or p50 antibodies. Following immunoprecipitation, the samples were incubated with Protein A/G Agarose (1 h, 4°C), and the immune complexes were collected by centrifugation (150 *g*, 5 min, 4°C), washed, and extracted with 1% SDS--0.1 M NaHCO~3~. After reversing the cross-linking, proteins were digested with proteinase K, and the samples were extracted with phenol/chloroform, followed by precipitation with ethanol. The pellets were re-suspended in nuclease-free water and subjected to real time PCR. Immunoprecipitated DNA was analyzed by real-time PCR (25 μl reaction mixture) using the iQ SYBR Green Supermix and the Bio-Rad MyIQ Single Color Real-Time PCR Detection System (Bio-Rad). Each immunoprecipitation was performed at least three times using different chromatin samples, and the occupancy was calculated by using the human IGX1A negative control primers (SA Biosciences, Frederick, MD, USA), which detect specific genomic ORF-free DNA sequence that does not contain binding site for any known transcription factors. The results were calculated as fold difference in occupancy of the particular protein at the particular locus in comparison with the IGX1A locus.

The IL-8 primers used for real time PCR were 5′-GGGCCATCAGTTGCAAATC-3′(forward), and 5′-GCTTGTGTGCTCTGCTGTCTC-3′(reverse).

Statistical analysis {#s4_10}
--------------------

The results represent at least three independent experiments. Numerical results are presented as means ± SE. Data were analyzed by using an InStat software package (GraphPAD, San Diego, CA, USA). Statistical significance was evaluated by using Mann-Whitney U test with Bonferroni correction for multiple comparisons, and *p* \< 0.05 was considered significant.
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